FrancophonIA/ELRC3.0 huggingface dataset:
English: In particular tell your doctor if you are taking medicines containing any of the following active substances as Agopton may affect the way these drugs work: - ketoconazole, itraconazole, rifampicin (used to treat infections) - digoxin (used to treat heart problems) - theophylline (used to treat asthma) - tacrolimus (used to prevent transplant rejection) - fluvoxamine (used to treat depression and other psychiatric diseases) - antacids (used to treat heartburn or acid regurgitation) - sucralfate (used for healing ulcers) - St John´s wort (Hypericum perforatum) (used to treat mild depression)
Danish: Det er særlig vigtigt at informere lægen, hvis De tager medicin, der indeholder et eller flere af de nedennævnte aktive stoffer, da Agopton og disse lægemidler kan påvirke hinandens effekt: - ketoconazol, itraconazol, rifampicin (mod infektioner) - digoxin (mod hjertesygdom) - theophyllin (mod astma)
English: Each oro-dispersible tablet contains <white to pale brownish white enteric-coated granules>.
Danish: Hver orodispersibel tablet indeholder <orange til mørkebrune mikrogranulater>.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each oro-dispersible tablet contains lansoprazole 15 mg
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver orodispersibel tablet indeholder 15 mg lansoprazol
English: Agopton 30 mg: Gastro-resistant granules for oral suspension.
Danish: Agopton 30 mg: Enterogranulater til peroral opløsning.
English: If your symptoms are not relieved within 4 weeks, please contact your doctor.
Danish: Kontakt lægen, hvis Deres symptomer ikke er blevet lindret i løbet af 4 uger.
English: Your doctor may have prescribed Agopton for another indication or with a dose different from that which is written in this information leaflet.
Danish: Kontakt lægen, skadestuen eller apoteket, hvis De har taget mere Agopton, end der står i denne indlægsseddel, eller mere end lægen har foreskrevet.
English: The following side effects are rare (occur in less than 1 in 1000 patients): - fever - restlessness, drowsiness, confusion, hallucinations, insomnia, visual disturbances, vertigo - a change in the way things taste, loss of appetite, inflammation of your tongue (glossitis) - skin reactions such as burning or pricking feeling under the skin, bruising, reddening and excessive sweating - sensitivity to light - hair loss - feelings of ants creeping over the skin (paresthesiae), trembling - anaemia (paleness) - kidney problems - pancreatitis - inflammation of the liver (may be seen as yellow skin or eyes) - breast swelling in males, impotence - candidiasis (fungal infection, may affect skin or the mucosa)
Danish: Følgende bivirkninger er sjældne (forekommer hos færre end 1 ud af 1.000 patienter): - feber - rastløshed, sløvhed, forvirring, hallucinationer, søvnløshed, synsforstyrrelser, vertigo - ændret smagssans, appetitløshed, betændelse i tungen (glossitis) - hudreaktioner som for eksempel en brændende eller prikkende følelse i huden, blå mærker,
English: Treatment of duodenal ulcer: one 30 mg oro-dispersible tablet every day for 2 weeks
Danish: Behandling af ulcus duodeni: 1 orodispersibel tablet (30 mg) hver dag i 2 uger.
English: Treatment of duodenal or stomach ulcer in patients requiring continued NSAID treatment: one 30 mg oro-dispersible tablet every day for 4 weeks.
Danish: Behandling af duodenalsår eller mavesår ved samtidig behandling med NSAID: 1 orodispersibel tablet (30 mg) hver dag i 4 uger.
English: ANNEX III SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
Danish: PRODUKTRESUMÉ, ETIKETTERING OG INDLÆGSSEDDEL
English: Agopton and associated names (see Annex I) 30 mg gastro-resistant granules for oral suspension [See Annex I - To be completed nationally]
Danish: Agopton og tilknyttede navne (se Bilag I) enterogranulater 30 mg til peroral opløsning [Se Bilag I - Udfyldes nationalt]
English: • Prophylaxis of NSAID-associated gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued therapy
Danish: • Profylakse af NSAID-relaterede gastriske ulcera, duodenale ulcera og lindring af symptomer hos patienter, der kræver fortsat behandling
English: The following side effects are rare (occur in less than 1 in 1000 patients): - fever - restlessness, drowsiness, confusion, hallucinations, insomnia, visual disturbances, vertigo - a change in the way things taste, loss of appetite, inflammation of your tongue (glossitis) - skin reactions such as burning or pricking feeling under the skin, bruising, reddening and excessive sweating - sensitivity to light - hair loss - feelings of ants creeping over the skin (paresthesiae), trembling - anaemia (paleness) - kidney problems - pancreatitis - inflammation of the liver (may be seen as yellow skin or eyes) - breast swelling in males, impotence - candidiasis (fungal infection, may affect skin or the mucosa) - angioedema; You should see your doctor immediately if you experience symptoms of angioedema,
Danish: rødmen og kraftig sveden - lysfølsomhed - hårtab - myrekryb (paræstesi), rysten - blodmangel (bleghed) - nyreproblemer - betændelse i bugspytkirtlen (pankreatitis) - leverbetændelse (kan ses ved gul hud eller gule øjne) - hævelse af bryster hos mænd, impotens - candidiasis (svampeinfektion, kan påvirke hud eller slimhinder) - angioødem; kontakt lægen omgående, hvis De oplever symptomer på angioødem som for eksempel hævet ansigt, tunge eller svælg, synkebesvær, nældefeber og åndedrætsbesvær.
English: • Treatment of NSAID-associated gastric ulcers, duodenal ulcers and gastroduodenal erosions, and relief of the associated symptoms, in patients requiring continued NSAID
Danish: • Behandling af NSAID-relaterede gastriske ulcera, duodenale ulcera og gastroduodenale erosioner samt lindring af de tilknyttede symptomer hos patienter, der kræver fortsat NSAID-behandling
English: Treatment of NSAID associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment:
Danish: Behandling af NSAID-associeret godartet ulcus ventriculi og ulcus duodeni hos patienter, der kræver fortsat NSAID-behandling:
English: Lactation:
Danish: Amning:
English: Pharmaceutical form Route of administration
Danish: Lægemiddelform Indgivelsesmåde
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each oro-dispersible tablet contains lansoprazole 30 mg
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver orodispersibel tablet indeholder 30 mg lansoprazol
English: • Treatment of NSAID-associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment
Danish: • Behandling af NSAID-relaterede godartede gastriske og duodenale ulcera hos patienter, der kræver fortsat NSAID-behandling
English: Agopton and associated names 15 mg oro-dispersible tablets Agopton and associated names 30 mg oro-dispersible tablets [See Annex 1- To be completed nationally] Lansoprazole
Danish: Agopton og tilknyttede navne orodispersible tabletter 15 mg Agopton og tilknyttede navne orodispersible tabletter 30 mg [Se Bilag I - Udfyldes nationalt] Lansoprazol
English: Treatment of duodenal or stomach ulcer in patients requiring continued NSAID treatment: one 30 mg capsule every day for 4 weeks.
Danish: Behandling af duodenalsår eller mavesår ved samtidig behandling med NSAID: 1 kapsel (30 mg) hver dag i 4 uger.
English: - Treatment of infections caused by the bacteria Helicobacter pylori when given in combination with antibiotic therapy - Treatment or prevention of duodenal or stomach ulcer in patients requiring continued NSAID
Danish: - Infektioner, der er forårsaget af bakterien Helicobacter pylori, når midlet kombineres med antibiotisk behandling - Behandling eller forebyggelse af duodenalsår eller mavesår hos patienter, der kræver samtidig behandling med NSAID'er (NSAID'er er midler, der anvendes mod smerter eller betændelsestilstande) - Behandling af Zollinger-Ellisons syndrom (kronisk dannelse af store mængder mavesyre).
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains lansoprazole 15 mg
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver kapsel indeholder 15 mg lansoprazol.
English: Treatment of heartburn and acid regurgitation: one 15 mg or 30 mg oro-dispersible tablet for 4 weeks.
Danish: Behandling af halsbrand og sure opstød: 1 orodispersibel tablet (15 mg eller 30 mg) hver dag i 4 uger.
English: Agopton and associated names 15 mg capsules Agopton and associated names 30 mg capsules [See Annex 1- To be completed nationally] Lansoprazole
Danish: Agopton og tilknyttede navne enterokapsler 15 mg Agopton og tilknyttede navne enterokapsler 30 mg [Se Bilag I - Udfyldes nationalt] Lansoprazol
English: - The active substance is lansoprazole - The other ingredients are
Danish: - Det aktive stof er lansoprazol.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each capsule contains lansoprazole 30 mg
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver kapsel indeholder 30 mg lansoprazol.
English: Posology and methods of administration
Danish: Dosering og indgivelsesmåde
English: Long-term prevention of reflux oesophagitis: one 15 mg oro-dispersible tablet every day, your doctor may adjust your dose to one 30 mg oro-dispersible tablet every day.
Danish: Langtidsforebyggelse af refluksøsofagitis: 1 orodispersibel tablet (15 mg) hver dag.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each single dose sachet contains lansoprazole 30 mg
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver enkeltdosispakke indeholder 30 mg lansoprazol
English: NAME OF THE MEDICINAL PRODUCT Agopton and associated names 15 mg capsules [See Annex I - To be completed nationally] lansoprazole
Danish: LÆGEMIDLETS NAVN Agopton og tilknyttede navne enterokapsler 15 mg [Se Bilag I - Udfyldes nationalt] lansoprazol
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients [To be completed nationally] 6.2 Incompatibilities Not applicable.
Danish: 6.2 Uforligeligheder Ikke relevant.
English: The tablet rapidly dissolves in the mouth, releasing microgranules which you should swallow without chewing.
Danish: Læg tabletten på tungen, og sug let på den. Tabletten opløses hurtigt i munden og frigiver enteromikrogranulater, som skal sluges uden at tygge på dem. Tabletten kan også synkes hel med et glas vand.
English: NAME OF THE MEDICINAL PRODUCT Agopton and associated names 30 mg capsules [See Annex I - To be completed nationally] lansoprazole
Danish: LÆGEMIDLETS NAVN Agopton og tilknyttede navne enterokapsler 30 mg [Se Bilag I - Udfyldes nationalt] lansoprazol
English: Treatment of stomach ulcer: one 30 mg capsule every day for 4 weeks
Danish: Behandling af ulcus ventriculi: 1 kapsel (30 mg) hver dag i 4 uger.
English: Symptoms of a hypersensitivity reaction may include fever, rash, swelling and sometimes a fall in blood pressure - inflammation of your mouth (stomatitis) - colitis (bowel inflammation) - changes in test values such as sodium, cholesterol and triglyceride levels - very severe skin reactions with reddening, blistering, severe inflammation and skin loss.
Danish: - mundbetændelse (stomatitis) - tarmbetændelse (colitis) - ændringer i analyseværdier af for eksempel natrium-, kolesterol- og triglyceridniveauer - meget alvorlige hudreaktioner med rødmen, blærer, alvorlig betændelse og hudtab - meget sjældent kan Agopton bevirke et fald i antallet af hvide blodlegemer, og Deres modstandskraft mod infektion kan være nedsat.
English: Treatment of inflammation in your oesophagus (reflux oesophagitis): one 30 mg capsule every day for 4 weeks
Danish: Behandling af betændelsestilstand i spiserøret (refluksøsofagitis): 1 kapsel (30 mg) hver dag i 4 uger.
English: Fluvoxamine:
Danish: Fluvoxamin:
English: Long-term prevention of reflux oesophagitis: one 15 mg capsule every day, your doctor may adjust your dose to one 30 mg capsule every day.
Danish: Langtidsforebyggelse af refluksøsofagitis: 1 kapsel (15 mg) hver dag.
English: Treatment of inflammation in your oesophagus (reflux oesophagitis): one 30 mg oro-dispersible tablet every day for 4 weeks
Danish: Behandling af betændelsestilstand i spiserøret (refluksøsofagitis): 1 orodispersibel tablet (30 mg) hver dag i 4 uger.
English: Treatment of stomach ulcer: one 30 mg oro-dispersible tablet every day for 4 weeks
Danish: Behandling af ulcus ventriculi: 1 orodispersibel tablet (30 mg) hver dag i 4 uger.
English: • Treatment of NSAID-associated benign gastric and duodenal ulcers in patients requiring continued
Danish: • behandling af NSAID-relaterede godartede gastriske og duodenale ulcera hos patienter, der kræver fortsat NSAID-behandling
English: • Treatment of reflux oesophagitis
Danish: • Behandling af refluksøsofagitis
English: Prevention of duodenal or stomach ulcer in patients requiring continued NSAID treatment: one 15 mg capsule every day, your doctor may adjust your dose to one 30 mg capsule every day.
Danish: Forebyggelse af duodenalsår eller mavesår ved samtidig behandling med NSAID: 1 kapsel (15 mg) hver dag.
English: NAME OF THE MEDICINAL PRODUCT Agopton and associated names 15 mg oro-dispersible tablet [See Annex I - To be completed nationally] lansoprazole
Danish: Agopton og tilknyttede navne orodispersible tabletter 15 mg [Se Bilag I - Udfyldes nationalt] lansoprazol
English: Hepatobiliary disorders
Danish: Dermatologiske lidelser
English: POSSIBLE SIDE EFFECTS
Danish: HVILKE MULIGE BIVIRKNINGER AGOPTON HAR
English: Gynaecomastia
Danish: PRODUKTRESUMÉ
English: Prevention of duodenal or stomach ulcer in patients requiring continued NSAID treatment: one 15 mg oro-dispersible tablet every day, your doctor may adjust your dose to one 30 mg oro-dispersible tablet every day.
Danish: Forebyggelse af duodenalsår eller mavesår ved samtidig behandling med NSAID: 1 orodispersibel tablet (15 mg) hver dag.
English: • Prophylaxis of reflux oesophagitis
Danish: • Profylakse af refluksøsofagitis
English: • Eradication and prevention of relapse of gastric ulcer and duodenal Two studies to support the indication prevention of duodenal ulcers were provided.
Danish: • Eradikation og forebyggelse af tilbagefald af gastriske og duodenale ulcera
English: If you have any further questions on the use of this product, ask your doctor.
Danish: Tal med Deres læge, hvis De har yderligere spørgsmål til behandlingen.
English: treatment
Danish: INDLÆGSSEDDEL
English: • Liver impairment
Danish: • Nedsat leverfunktion
English: PACKAGE LEAFLET
Danish: Smeltetabletter
English: Date of first authorisation: 18 January 2017
Danish: Dato for første markedsføringstilladelse: 18. januar 2017
English: Unopened vial: 3 years.
Danish: Uåbnet hætteglas: 3 år.
English: Activity in vitro and in vivo
Danish: Aktivitet in vitro og in vivo
English: Your dose will be calculated using your body weight.
Danish: Din dosis bliver beregnet ud fra din kropsvægt.
English: Common (may affect up to 1 in 10 people)
Danish: Almindelig (kan forekomme hos op til 1 ud af 10 personer):
English: From a microbiological point of view, the product must be used immediately.
Danish: Ud fra en mikrobiologisk synsvinkel skal præparatet bruges med det samme.
English: Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Danish: Læs denne indlægsseddel grundigt, inden du bliver behandlet med dette lægemiddel, da den indeholder vigtige oplysninger.
English: • You will get ZINPLAVA in one dose and it will take about 1 hour.
Danish: • Du vil kun få en dosis af Zinplava, og det vil tage omkring 1 time.
English: Genotoxicity and carcinogenic potential have not been evaluated.
Danish: Det genotoksiske og karcinogene potentiale er ikke blevet undersøgt.
English: • When people get CDI, they are usually given an antibiotic to get rid of the infection, but CDI can often come back within weeks or months.
Danish: • Når personer får CDI, får de sædvanligvis et antibiotikum for at slippe af med infektionen, men CDI kan ofte komme igen inden for uger eller måneder.
English: • If you are pregnant or trying to get pregnant, tell your doctor.
Danish: • Hvis du er gravid eller prøver på at blive gravid, skal du fortælle det til lægen.
English: Infected with a hypervirulent strain
Danish: Inficeret med en hypervirulent stamme
English: No formal interactions studies with other medicinal products were conducted.
Danish: Der er ikke udført formelle interaktionsstudier med andre lægemidler.
English: Characteristic at study entry
Danish: Karakteristikum ved indtræden i studie
English: • It is very important that you do not miss the dose of this medicine.
Danish: • Det er meget vigtigt, at du ikke springer infusionen med dette lægemiddel over.
English: It binds to C. difficile toxin B.
Danish: Det binder til C. difficile-toksin B.
English: These patients presented with risk factors primarily but not exclusively associated with higher risk of CDI recurrence.
Danish: Disse patienter havde risikofaktorer, som primært, men ikke udelukkende, var forbundet med en højere risiko for recidiv af CDI.
English: ATC code: J06BB21
Danish: ATC-kode: J06BB21
English: The following side effects have been reported in clinical trials:
Danish: Følgende bivirkninger er rapporteret i kliniske studier:
English: • You and your doctor should decide together if you will use ZINPLAVA.
Danish: • Du og lægen skal sammen afgøre, om du skal have Zinplava.
English: The safety profile of ZINPLAVA was assessed in two Phase 3 clinical studies.
Danish: ZINPLAVAs sikkerhedsprofil blev vurderet i to kliniske fase 3-studier.
English: Adjusted Difference (95% CI)
Danish: Justeret forskel (95 % CI)
English: † See Description of selected adverse reactions below.
Danish: † Se Beskrivelse af udvalgte bivirkninger nedenfor.
English: • You should keep taking your antibiotic for CDI as directed by your doctor.
Danish: • Du skal fortsætte med at tage dit antibiotikum mod CDI som foreskrevet af lægen.
English: Children and adolescents ZINPLAVA should not be used in children and adolescents below 18 years of age.
Danish: Børn og unge Zinplava må ikke anvendes til børn og unge under 18 år.
English: Fertility studies have not been conducted in animals.
Danish: Der er ikke udført fertilitetsstudier hos dyr.
English: • Call your doctor or health care professional right away to reschedule your appointment.
Danish: • Kontakt straks lægen eller sundhedspersonalet for at få en ny aftale.
English: Overall, 51 % were ≥ 65 years, 29% were ≥ 75 years and 39 % received one or more systemic antibacterial agents during the 12 week follow-up period.
Danish: Overordnet set var 51 % ≥ 65 år, 29 % var ≥ 75 år, og 39 % fik et eller flere systemiske antibakterielle midler i opfølgningsperioden på 12 uger.
English: Of the total 28 % had one or more episodes of CDI within the six months prior to the episode under treatment (18 % of the patients had one, 7 % had two and a few patients had 3 or more prior episodes).
Danish: Af det samlede antal patienter havde 28 % haft en eller flere episoder med CDI inden for 6 måneder forud for den episode, der blev behandlet (18 % af patienterne havde haft en, 7 % havde haft to, og få patienter havde haft 3 eller flere forudgående episoder).
English: Industriepark 30 - Zone A 2220 Heist-op-den-Berg Belgium
Danish: Industriepark 30 - Zone A 2220 Heist-op-den-Berg Belgien
English: Immunogenicity of ZINPLAVA was evaluated using an electrochemiluminescence (ECL) assay in MODIFY I and MODIFY II.
Danish: Immunogeniciteten af ZINPLAVA blev vurderet ved hjælp af en elektrokemiluminescensanalyse (ECL) i MODIFY I og MODIFY II.
English: ZINPLAVA should not be used during pregnancy unless the clinical condition of the woman requires treatment with bezlotoxumab.
Danish: ZINPLAVA bør ikke anvendes under graviditet, medmindre kvindens kliniske tilstand kræver behandling med bezlotoxumab.
English: There are limited data from the use of bezlotoxumab in pregnant women.
Danish: Der er begrænsede data fra anvendelse af bezlotoxumab til gravide kvinder.
English: In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment should be instituted.
Danish: I tilfælde af overdosering skal patienten monitoreres nøje for symptomer på bivirkninger og passende symptomatisk behandling iværksættes.
English: Following treatment with ZINPLAVA in MODIFY I and MODIFY II, none of the 710 evaluable patients tested positive for treatment-emergent anti-bezlotoxumab antibodies.
Danish: Efter behandling med ZINPLAVA i MODIFY I og MODIFY II blev ingen af de 710 evaluerbare patienter testet positive for behandlingsrelaterede antistoffer mod bezlotoxumab.
English: Table 1: Adverse Reactions with ZINPLAVA MedDRA System Organ Class
Danish: Tabel 1: Bivirkninger ved ZINPLAVA MedDRA-systemorganklasse
English: Do not use the vial if the solution is discoloured or contains visible particles.
Danish: Brug ikke hætteglasset, hvis koncentratet er misfarvet eller indeholder synlige partikler.
English: You can also report side effects directly the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Danish: Du eller dine pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel.
English: Keep vial in the outer carton in order to protect from light.
Danish: Opbevar hætteglasset i den ydre karton for at beskytte mod lys.
English: • We don't know if ZINPLAVA will harm your baby while you are pregnant.
Danish: • Det vides ikke, om Zinplava vil skade dit ufødte barn, hvis du får det, mens du er gravid.
English: In the studies, the clinical cure rates of the presenting CDI episode were comparable between the treatment arms.
Danish: I studierne var de kliniske helbredelsesrater for den foreliggende CDI-episode sammenlignelige mellem behandlingsarmene.
English: • ZINPLAVA must not be co-administered with other medicinal products simultaneously through the same infusion line.
Danish: • ZINPLAVA må ikke administreres samtidigt med andre lægemidler i samme infusionsslange.
English: Hypervirulent strain included the following: 027, 078, or 244 ribotypes
Danish: Hypervirulent stamme omfattede følgende: ribotype 027, 078 eller 244.
English: Twenty one (21) percent of the patients were immunocompromised and 16 % presented with clinically severe CDI.
Danish: 21 % af patienterne var immunkompromitterede, og 16 % havde klinisk svær CDI.
English: Talk to your doctor before you are given ZINPLAVA.
Danish: Tal med lægen, før du får Zinplava.
English: Because monoclonal antibodies may be excreted in human milk, a decision should be made whether to discontinue breast-feeding or to not administer ZINPLAVA, taking into account the importance of ZINPLAVA to the mother.
Danish: Da monoklonale antistoffer kan udskilles i human mælk, skal det besluttes, om amning eller behandling med ZINPLAVA skal ophøre, idet der tages hensyn til vigtigheden af ZINPLAVA-behandling for moderen.
English: • You will get ZINPLAVA as an infusion (drip) into a vein.
Danish: • Du vil få Zinplava som en infusion i en vene (et drop).
English: A similar proportion of patients were receiving oral metronidazole (48 %) or oral vancomycin (48 %) and only 4 % were receiving fidaxomicin as antibacterial treatment for CDI.
Danish: Et sammenligneligt antal patienter fik oralt metronidazol (48 %) eller oralt vancomycin (48 %), og kun 4 % fik fidaxomicin som antibakteriel behandling mod CDI.
English: If you miss an appointment to get ZINPLAVA
Danish: Hvis du glemmer en aftale om at få Zinplava
English: There is no data regarding the efficacy of ZINPLAVA if given after the initial 10- to 14-days of antibacterial therapy for CDI.
Danish: Der foreligger ingen data vedrørende ZINPLAVAs virkning, hvis det gives efter de første 10 til 14 dages antibakterielle behandling mod CDI.